Phase 2 Study of Anlotinib in Advanced Medullary Thyroid Carcinoma
Phase of Trial: Phase II
Latest Information Update: 22 May 2019
Price : $35 *
At a glance
- Drugs Anlotinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 20 May 2019 Status changed from active, no longer recruiting to completed.
- 07 Jun 2016 Primary endpoint (Progression free survival) has been met, according to the results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2016 Results assessing safety and efficacy, presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.